2024 Feb 27

New search has been performed

A search of the CF Group's CF Trials Register identified 41 new references potentially eligible for inclusion in the review.

Eight new references were added to two already included studies (Saiman 2003; Saiman 2010), four new references were added to three already excluded studies (Baumann 2000; Dogru 2004; Pukhalsky 2001) and two new references were added to one study previously awaiting assessment, but now excluded (Elmasry 2010).

Seventeen references to four studies were newly included in the review (COMBAT CF 2022; Maneshi 2019; Nichols 2020; OPTIMIZE 2018), one new reference was excluded (Nick 2014) and four references to three studies were put in awaiting classification (EUCTR2019‐003501‐10‐DK; Hansen 2015; NCT00411736). Five references were deleted as they did not meet the inclusion criteria.

A search of trial registries identified 25 unique trials for potential inclusion. Two trials were added to already included studies (COMBAT CF 2022; Saiman 2010) and one trial was added to studies awaiting classification (NCT00298922). The remaining 22 references were deleted as they did not meet the inclusion criteria for this review.

At this update, we included four new studies (COMBAT CF 2022; Maneshi 2019; Nichols 2020; OPTIMIZE 2018).

2024 Feb 27

New citation required but conclusions have not changed

Despite the inclusion of four new studies to this review, the conclusions remain the same.

One author (Pierre Barker) has stepped down from the author team. Two new authors (Sherie Smith and Dominiki Kurz) have joined the review team.

2012 Sep 11

New search has been performed

A search of the Group's Cystic Fibrosis Trials Register identified five new additional references to a study already included in the review (Saiman 2010). There was some additional information identified on serum inflammatory markers, but we have only been able to include a narrative description of this so far. Data were skewed and presented as log‐transformed data; we are awaiting the non‐transformed data from the authors.

2012 Sep 11

New citation required but conclusions have not changed

Some additional narrative information has been added about serum inflammatory markers; however, the conclusions of the review remain the same.

2011 Oct 20

New citation required and conclusions have changed

Due to an editorial error this review should have been flagged as a new citation due to the inclusion of large amounts of new data leading to a change in conclusions.

2011 Feb 09

New search has been performed

A search of the Group's Cystic Fibrosis Trials Register identified 18 new references.

Five new references were to three new studies which have been included (Kabra 2010; O'Connor 2009; Saiman 2010).

Four new references were to one study previously listed as ongoing which has now been included (McCormack 2007).

Two new references were to a study previously listed as 'Awaiting classification' (Steinkamp 2007). This study has now been included.

Two studies (with no new references found) previously listed as 'Awaiting classification' have now been included (Clement 2006; Rotschild 2005).

Four new references to two new studies have been excluded (Aaron 2005; Shmarina 2004).

We found one new additional reference to a study previously listed under 'Awaiting classification'; the study has now been excluded (Rubin 2003).

Seven studies previously listed as 'Awaiting classification' have now been excluded (Anstead 2001; Beringer 2005; Dionyssopoulou 2005; Dogru 2004; Frederiksen 2001; Kessaris 2003; Sriram 2003).

One study which was previously included has now been removed from the review as it is an open label pharmacokinetic study (Cipolli 2001). This has had no bearing on the overall conclusions.

Two new studies have been listed as 'Awaiting classification' (Elmasry 2010; Pukhalsky 2001).

A new plain language summary has been drafted in line with current guidance from The Cochrane Collaboration.

2010 Mar 09

New search has been performed

A search of the Group's Cystic Fibrosis Trials Register identified 18 new references.

Five new references were to three new studies which have been included (Kabra 2010; O'Connor 2009; Saiman 2010).

Four new references were to one study previously listed as ongoing which has now been included (McCormack 2007).

Two new references were to a study previously listed as 'Awaiting classification' (Steinkamp 2007). This study has now been included.

Two studies (with no new references found) previously listed as 'Awaiting classification' have now been included (Clement 2006; Rotschild 2005).

Four new references to two new studies have been excluded (Aaron 2005; Shmarina 2004).

We found one new additional reference to a study previously listed under 'Awaiting classification'; the study has now been excluded (Rubin 2003).

Seven studies previously listed as 'Awaiting classification' have now been excluded (Anstead 2001; Beringer 2005; Dionyssopoulou 2005; Dogru 2004; Frederiksen 2001; Kessaris 2003; Sriram 2003).

One study which was previously included has now been removed from the review as it is an open label pharmacokinetic study (Cipolli 2001). This has had no bearing on the overall conclusions.

Two new studies have been listed as 'Awaiting classification' (Elmasry 2010; Pukhalsky 2001).

A new plain language summary has been drafted in line with current guidance from The Cochrane Collaboration.

2008 Nov 12

Amended

Converted to new review format.

2006 Feb 13

New search has been performed

After a search of the Group's Cystic Fibrosis Register, a total of nine studies have been added to the review: one to the list of excluded studies (Jensen 2005); five to studies awaiting assessment (Beringer 2005; Clement 2005; Dionyssopoulou 2005; Dogru 2004; Kessaris 2003); and three to the list of ongoing studies (AZ003; AZ004; Rubin 2003).

2017 May 10

Amended

Converted to new review format.